Zobrazeno 1 - 4
of 4
pro vyhledávání: '"упадацитиниб"'
Autor:
A. E. Cheberda, D. Yu. Belousov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 96-107 (2024)
Aim. To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods. Randomized controlled tri
Externí odkaz:
https://doaj.org/article/17035698925941c8bfee596dca472743
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 70-84 (2023)
Objective. Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment of moderate to severe atopic dermatitis.Materials and methods. Study design — retrospective. Pharmacoeconomic analysis method — cost-e
Externí odkaz:
https://doaj.org/article/d904af2afb0842bd8bf9ad1aacfb463f
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 17-29 (2022)
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib). A
Externí odkaz:
https://doaj.org/article/c1cc2692cb7e45bdb9c7a29ede8acfe5
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 40-51 (2020)
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods. Study Design — Retrospective Analysisof Lit
Externí odkaz:
https://doaj.org/article/6730714bb93a47e5aba8f30767e5f092